This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Age-Related Macular Degeneration (AMD) market through 2031.
Drug sales in the AMD pharmacotherapy market are expected to grow by a significant margin between 2021 and 2031, with an overall compound annual growth rate (CAGR) of 14.1% over the forecast period. In 2021, the Publisher estimated the total AMD market to be valued at $7.4 billion across the 7MM, with the US accounting for 51.7% of the market. The five major European markets (5EU) (France, Germany, Italy, Spain, and UK) accounted for 40.8% of the global AMD market with an estimated value of $3.0 billion, and Japan’s AMD market was estimated to be $550.8 million in 2021, accounting for 7.5% of the market.
Over the forecast period, the AMD market is anticipated to grow to a value of $27.5 billion in 2031, with the US anticipated to account for 72.1% of the global market and a market value of $19.8 billion. The US is anticipated to experience the fastest growth during this period with a CAGR of 18.0%, while the 5EU is anticipated to grow at a CAGR of 9.0% to reach a market value of $7.1 billion in 2031. Japan is anticipated to witness the slowest growth among the 7MM with a CAGR of 0.4% during the forecast period and a market value of $570.9 million in 2031.
Forecast covers the period 2021-2031.
2021 base year sales within the AMD market are approximately $7.4 billion across the 7MM detailed in this report. The publisher estimates that the AMD market will grow at a compound annual growth rate (CAGR) of 14.1% to reach $27.5 billion by the end of the forecast period.
Drug sales in the AMD pharmacotherapy market are expected to grow by a significant margin between 2021 and 2031, with an overall compound annual growth rate (CAGR) of 14.1% over the forecast period. In 2021, the Publisher estimated the total AMD market to be valued at $7.4 billion across the 7MM, with the US accounting for 51.7% of the market. The five major European markets (5EU) (France, Germany, Italy, Spain, and UK) accounted for 40.8% of the global AMD market with an estimated value of $3.0 billion, and Japan’s AMD market was estimated to be $550.8 million in 2021, accounting for 7.5% of the market.
Over the forecast period, the AMD market is anticipated to grow to a value of $27.5 billion in 2031, with the US anticipated to account for 72.1% of the global market and a market value of $19.8 billion. The US is anticipated to experience the fastest growth during this period with a CAGR of 18.0%, while the 5EU is anticipated to grow at a CAGR of 9.0% to reach a market value of $7.1 billion in 2031. Japan is anticipated to witness the slowest growth among the 7MM with a CAGR of 0.4% during the forecast period and a market value of $570.9 million in 2031.
Key Highlights
Report deliverables include a Pdf report and an Excel-based forecast model
Forecast includes the 7 major markets (7MM)Forecast covers the period 2021-2031.
2021 base year sales within the AMD market are approximately $7.4 billion across the 7MM detailed in this report. The publisher estimates that the AMD market will grow at a compound annual growth rate (CAGR) of 14.1% to reach $27.5 billion by the end of the forecast period.
Scope
- Overview of AMD, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized AMD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the AMD market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for AMD. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the 7MM AMD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM AMD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM VTE therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
- About the Publisher
1 Age-Related Macular Degeneration: Executive Summary
2 Introduction
3 Disease Overview
4 Epidemiology
5 Disease Management
6 Competitive Assessment
7 Unmet Needs and Opportunity Assessment
8 R&D Strategies
9 Pipeline Assessment
10 Pipeline Valuation Analysis
11 Current and Future Players
12 Market Outlook
13 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Regeneron
- Bayer
- Roche
- Novartis
- AbbVie
- RegenxBio
- Outlook Therapeutics
- Kodiak Sciences
- Opthea
- Apellis Pharmaceuticals
- Iveric Bio
- Genentech
- Chugai
- Bausch + Lomb
- Clinigen
- Cheplapharm
- Ribomic
- Unity Biotechnology
- Clearside Biomedical
- EyePoint Pharmaceuticals
- Ocular Therapeutix
- Ashvattha Therapeutics
- Outlook Therapeutics
- Adverum Biotechnlologies
- Formycon
- Essex Bio
- Xbrane Biopharma
- Celltrion
- Lupin
- Viatris
- Amgen
- Samsung Bioepis
- Senju
- SamChunDang Pharm Co Ltd
